Connect
Welcome to the online home of the Chris M. Carlos and Catherine Nicole Jockisch Carlos Endowment for Primary Sclerosing Cholangitis (PSC). Thanks to support provided by this endowment, dedicated Mayo Clinic investigators and their teams are making strides to better understand and treat PSC patients, with the ultimate goal of developing a cure for this disease.
Follow the PSC page and stay up-to-date as we post news about advances in PSC research, clinical trials, and available resources.
Public blog
Newsfeed
Absence of medical therapy for primary sclerosing cholangitis (PSC) leads to end-stage liver disease requiring liver transplantation (LT). However, studies specifically evaluating whether ethnic disparities…
Autoimmune liver disease (AILD) is thought to result from a complex interplay between genetics and the environment. In the Journal of Hepatology, Dyson, et al.,…
To influence host and disease phenotype, compositional microbiome changes, which have been demonstrated in patients with primary sclerosing cholangitis (PSC), must be accompanied by functional…
Altered bile acid (BA) homeostasis, an intrinsic facet of cholestic liver diseases, in primary sclerosing cholangitis (PSC) remains understudied. In a recent publication in Hepatology.…
Early detection of perihilar cholangiocarcinoma (CCA) among patients with primary sclerosing cholangitis (PSC) is important to identify those patients eligible for curative therapy. In a…
Single measurements of liver stiffness (LS) by magnetic resonance elastography (MRE) have been associated with outcomes of patients with primary sclerosing cholangitis (PSC). In…
Liver transplantation (LT) remains the mainstay therapy of primary sclerosing cholangitis (PSC). In a recent publication, Berenguer et al., examined the influence of sex on…
Clinical Trials are a fundamental aspect of our research and clinical efforts for Primary Sclerosing Cholangitis (PSC) at Mayo Clinic. At the present time, we…
In a recent paper, published in the Journal of Hepatology, Kowdley, et al., reported a randomized, placebo-controlled, dose-finding study of Obeticholic acid (OCA), which has…
In a recent study, published in the journal Clinical Gastroenterology and Hepatology, Hedin, et al., reported the effects of tumor necrosis factor (TNF) antagonists on…
In a recent paper published in the Journal of Gastroenterology, Bakhshi et al., reported an update on the epidemiology and outcomes of Primary Sclerosing Cholangitis (PSC)…
In a recent study, published in the journal Hepatology, Goeppert B. et al., reported genomic features of cholangiocarcinoma (i.e., bile duct cancer) in patients with…
Mayo Clinic in Minnesota, Arizona and Florida is currently conducting a randomized placebo controlled clinical trial, examining the impact of oral vancomycin on markers of…
In a recent paper, published in the Journal Clinical Gastroenterology and Hepatology, Eaton et al., found that measuring liver stiffness of patients suffering from PSC…
In a recent paper published in the journal Clinical Gastroenterology and Hepatology, Stokkeland K. et al., reported the effects of exposure to medications on the…
Primary Sclerosing Cholangitis (PSC) is a slowly progressing disease that affects both adults and children. Several of the clinical features of the disease are different…
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease that affects about 1 in 10,000 people. In this presentation, Robert C. Huebert, M.D, an…
Meaningful and reliable predictors of disease progression in PSC are currently lacking despite efforts over the past three decades. Patients with PSC often demonstrate increased…
Aging (senescent) bile duct cells , i.e., cholangiocytes, demonstrate an arrest of the cell cycle, hypersecretion of inflammatory molecules and resistance to cell death. O’Hara…
About 50 percent of patients with Primary Sclerosing Cholagnitis (PSC) have no symptoms. Yet, patients with PSC have abnormal laboratory tests, which fluctuate over time…
Connect